| Drug Name | ***0005 |
| Description |
A cancer immunotherapy consisting of human autologous T cells expressing CXCR5 and a chimeric antigen receptor (CAR) targeting human epidermal growth factor receptor (EGFR) is in a phase I clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC). |
| Target | Epidermal Growth Factor Receptor (EGFR) |
| Drug Modality | CAR T cells |
| Indication | Non-Small Cell Lung Cancer (NSCLC) |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Targeting EGFR-expressing tumor cells to induce selective cytotoxicity and cytolysis |
| Status | Phase I |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |